Study_Design_MERIT_Trial_Presentation.pptx

Study design of merit trial presentation

1. Study Design of the MERIT Trial - **Type:** Multicenter, randomized (1:1:1), parallel-treatment, comparative effectiveness trial - **Participants:** Patients with recurrent or persistent ME and inactive or minimally active uveitis - **Hypotheses:** 1. Methotrexate vs. dexamethasone (Ozurdex; Allergan) 2. Ranibizumab (Lucentis; Genentech) vs. dexamethasone - **Secondary Outcomes:** Best-corrected visual acuity (BCVA), incidence of ocular side effects - **Clinical Centers:** 33 centers (18 in the US, 9 in the UK, 4 in India, 1 in Australia, 1 in Canada) - **Ethics:** Approved by institutional review boards, followed Declaration of Helsinki principles, registered at ClinicalTrials.gov (NCT02623426)